Nail Problems Surge Among GLP-1 Users, Study Reveals
A recent study highlights a significant increase in nail issues among users of GLP-1 medications like Ozempic, with nail detachment reported in 39% of cases.
39% of GLP-1 users experienced nail detachment compared to 9% in non-users.
66% of those on GLP-1 drugs reported some form of nail trouble.
The study suggests other factors may contribute to nail issues beyond weight loss.
A new study presented at the 2026 European Academy of Dermatology and Venereology Congress has revealed alarming findings regarding nail health among users of GLP-1 medications such as Ozempic and Wegovy. Researchers found that nail detachment, a condition where the nail separates from the nail bed, was reported by 39% of GLP-1 users, significantly higher than the 9% observed in a control group of individuals who had never used these drugs.
The study involved 575 participants using GLP-1 receptor agonists, compared with 1,329 individuals with type 2 diabetes or obesity who were not on these medications. The results indicated that not only was nail detachment prevalent, but other nail issues, including discoloration, were also more common among GLP-1 users, with 46% reporting discoloration compared to 17% in the control group. Overall, 66% of GLP-1 users experienced at least one nail-related problem, raising concerns about the broader implications of these medications.
Despite these findings, researchers caution against hastily attributing nail problems solely to GLP-1 drugs. Many participants had pre-existing nail issues prior to starting treatment, and factors such as nutritional deficiencies and underlying skin conditions may also play a role. The study does not establish a direct cause-and-effect relationship, and researchers are exploring whether the observed nail issues are linked to the medications themselves or other factors.
The implications of these findings extend beyond individual health, as they highlight the need for healthcare providers to be aware of potential side effects associated with GLP-1 therapy. As these medications become increasingly popular for managing obesity and diabetes, understanding their full range of effects, including those on hair and nails, is crucial for patient care. Dermatologists are now advising patients experiencing persistent changes to consult with healthcare professionals before making any decisions about their treatment.
Looking ahead, further research is necessary to clarify the mechanisms behind these nail issues and to determine the long-term effects of GLP-1 medications. As more individuals begin and continue treatment with these drugs, ongoing studies will be essential to ensure that both patients and healthcare providers are informed about potential side effects and can manage them effectively.
